MX2017005672A - Erradicacion guiada de arn de virus jc mano y otros poliomavirus. - Google Patents

Erradicacion guiada de arn de virus jc mano y otros poliomavirus.

Info

Publication number
MX2017005672A
MX2017005672A MX2017005672A MX2017005672A MX2017005672A MX 2017005672 A MX2017005672 A MX 2017005672A MX 2017005672 A MX2017005672 A MX 2017005672A MX 2017005672 A MX2017005672 A MX 2017005672A MX 2017005672 A MX2017005672 A MX 2017005672A
Authority
MX
Mexico
Prior art keywords
polyomaviruses
virus
eradication
man
rna guided
Prior art date
Application number
MX2017005672A
Other languages
English (en)
Inventor
Khalili Kamel
Wenhui
WOLLEBO Hassen
Original Assignee
Univ Temple
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Temple filed Critical Univ Temple
Publication of MX2017005672A publication Critical patent/MX2017005672A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases RNAses, DNAses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

La presente invención incluye métodos y composiciones para la eliminación de poliomavirus, tales como Virus John Cunningham (JVC), de células huésped, y el tratamiento de enfermedades relacionadas con poiliomavirus, tales como leucoencefalopatía multifocal progresiva (PML). Las composiciones incluyen secuencias de ácido nucleico aislado que comprenden una endonucleasa asociada con CRISPR y un ARN de guía, en donde el ARN de guía es complementario a una secuencia objetivo en un poliomavirus.
MX2017005672A 2014-10-30 2015-10-30 Erradicacion guiada de arn de virus jc mano y otros poliomavirus. MX2017005672A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462072927P 2014-10-30 2014-10-30
US201562169390P 2015-06-01 2015-06-01
US201562169638P 2015-06-02 2015-06-02
PCT/US2015/058351 WO2016070070A1 (en) 2014-10-30 2015-10-30 Rna guided eradication of human jc virus and other polyomaviruses

Publications (1)

Publication Number Publication Date
MX2017005672A true MX2017005672A (es) 2018-11-09

Family

ID=55858408

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017005672A MX2017005672A (es) 2014-10-30 2015-10-30 Erradicacion guiada de arn de virus jc mano y otros poliomavirus.

Country Status (11)

Country Link
US (2) US20170333572A1 (es)
EP (1) EP3212795A4 (es)
CN (2) CN107406854B (es)
AU (1) AU2015338993B2 (es)
CA (1) CA2967990C (es)
HK (1) HK1247636A1 (es)
MA (1) MA40880A (es)
MX (1) MX2017005672A (es)
RU (1) RU2747722C2 (es)
WO (1) WO2016070070A1 (es)
ZA (1) ZA201703163B (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012333134B2 (en) 2011-07-22 2017-05-25 John Paul Guilinger Evaluation and improvement of nuclease cleavage specificity
EP2841572B1 (en) 2012-04-27 2019-06-19 Duke University Genetic correction of mutated genes
US9163284B2 (en) 2013-08-09 2015-10-20 President And Fellows Of Harvard College Methods for identifying a target site of a Cas9 nuclease
US9359599B2 (en) 2013-08-22 2016-06-07 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
US9340800B2 (en) 2013-09-06 2016-05-17 President And Fellows Of Harvard College Extended DNA-sensing GRNAS
US9388430B2 (en) 2013-09-06 2016-07-12 President And Fellows Of Harvard College Cas9-recombinase fusion proteins and uses thereof
US9737604B2 (en) 2013-09-06 2017-08-22 President And Fellows Of Harvard College Use of cationic lipids to deliver CAS9
US9068179B1 (en) 2013-12-12 2015-06-30 President And Fellows Of Harvard College Methods for correcting presenilin point mutations
AU2015298571B2 (en) 2014-07-30 2020-09-03 President And Fellows Of Harvard College Cas9 proteins including ligand-dependent inteins
US11970710B2 (en) 2015-10-13 2024-04-30 Duke University Genome engineering with Type I CRISPR systems in eukaryotic cells
WO2017070632A2 (en) 2015-10-23 2017-04-27 President And Fellows Of Harvard College Nucleobase editors and uses thereof
CN108473527A (zh) * 2015-12-09 2018-08-31 切除生物治疗公司 用于消除免疫抑制疗法期间jc病毒激活和pml(进行性多灶性白质脑病)风险的基因编辑方法和组合物
US20190038770A1 (en) * 2016-01-25 2019-02-07 Excision Biotherapeutics,Inc. Rna guided eradication of human jc virus and other polyomaviruses
US20190161743A1 (en) * 2016-05-09 2019-05-30 President And Fellows Of Harvard College Self-Targeting Guide RNAs in CRISPR System
US20200095586A1 (en) * 2016-06-01 2020-03-26 Excision Biotherapeutics, Inc. Compositions and methods of treatment for lytic and lysogenic viruses
EP3487523B1 (en) * 2016-07-19 2023-09-06 Duke University Therapeutic applications of cpf1-based genome editing
CA3032699A1 (en) 2016-08-03 2018-02-08 President And Fellows Of Harvard College Adenosine nucleobase editors and uses thereof
WO2018031683A1 (en) 2016-08-09 2018-02-15 President And Fellows Of Harvard College Programmable cas9-recombinase fusion proteins and uses thereof
WO2018039438A1 (en) 2016-08-24 2018-03-01 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
EP3526320A1 (en) 2016-10-14 2019-08-21 President and Fellows of Harvard College Aav delivery of nucleobase editors
US10745677B2 (en) 2016-12-23 2020-08-18 President And Fellows Of Harvard College Editing of CCR5 receptor gene to protect against HIV infection
EP3592853A1 (en) 2017-03-09 2020-01-15 President and Fellows of Harvard College Suppression of pain by gene editing
JP2020510439A (ja) 2017-03-10 2020-04-09 プレジデント アンド フェローズ オブ ハーバード カレッジ シトシンからグアニンへの塩基編集因子
KR102687373B1 (ko) 2017-03-23 2024-07-23 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 핵산 프로그램가능한 dna 결합 단백질을 포함하는 핵염기 편집제
WO2018209320A1 (en) 2017-05-12 2018-11-15 President And Fellows Of Harvard College Aptazyme-embedded guide rnas for use with crispr-cas9 in genome editing and transcriptional activation
EP3658573A1 (en) 2017-07-28 2020-06-03 President and Fellows of Harvard College Methods and compositions for evolving base editors using phage-assisted continuous evolution (pace)
WO2019139645A2 (en) 2017-08-30 2019-07-18 President And Fellows Of Harvard College High efficiency base editors comprising gam
CN111757937A (zh) 2017-10-16 2020-10-09 布罗德研究所股份有限公司 腺苷碱基编辑器的用途
WO2020191249A1 (en) 2019-03-19 2020-09-24 The Broad Institute, Inc. Methods and compositions for editing nucleotide sequences
EP4058050A4 (en) * 2019-11-11 2023-11-29 Temple University of the Commonwealth System of Higher Education CRISPR/CAS9 SYSTEM AS AN AGENT FOR INHIBITING JC POLYOMA INFECTION
MX2022014008A (es) 2020-05-08 2023-02-09 Broad Inst Inc Métodos y composiciones para la edición simultánea de ambas cadenas de una secuencia de nucleótidos de doble cadena objetivo.
CN112322587A (zh) * 2020-09-17 2021-02-05 杭州市第一人民医院 一种带Cas9基因的人源可诱导多能干细胞系、构建方法、鉴定方法及应用
RU2747820C1 (ru) * 2020-11-30 2021-05-14 Федеральное бюджетное учреждение науки «Центральный научно-исследовательский институт эпидемиологии» Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека (ФБУН ЦНИИ Эпидемиологии Роспотребнадзора) Система CRISPR-Cas для выявления ДНК вируса Джона Каннингема (JCPyV) в ультранизких концентрациях
RU2747819C1 (ru) * 2020-11-30 2021-05-14 Федеральное бюджетное учреждение науки «Центральный научно-исследовательский институт эпидемиологии» Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека (ФБУН ЦНИИ Эпидемиологии Роспотребнадзора) Способ получения препарата рибонуклеопротеинового комплекса CRISPR/Cas и препарат для выявления ДНК вируса Джона Каннингема (JCPyV) в ультранизких концентрациях

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6054312A (en) * 1997-08-29 2000-04-25 Selective Genetics, Inc. Receptor-mediated gene delivery using bacteriophage vectors
JP4812874B2 (ja) * 2006-04-28 2011-11-09 アルナイラム ファーマシューティカルズ， インコーポレイテッド Ｊｃウイルス遺伝子の発現を抑制するための組成物および方法
WO2014113493A1 (en) * 2013-01-16 2014-07-24 Emory University Cas9-nucleic acid complexes and uses related thereto

Also Published As

Publication number Publication date
US20170333572A1 (en) 2017-11-23
US20230001016A1 (en) 2023-01-05
ZA201703163B (en) 2019-03-27
MA40880A (fr) 2017-09-05
CN107406854B (zh) 2022-03-11
EP3212795A1 (en) 2017-09-06
AU2015338993B2 (en) 2021-12-09
CA2967990C (en) 2024-02-13
RU2017115838A3 (es) 2018-11-30
RU2747722C2 (ru) 2021-05-13
RU2017115838A (ru) 2018-11-30
CN107406854A (zh) 2017-11-28
EP3212795A4 (en) 2018-06-27
WO2016070070A1 (en) 2016-05-06
CA2967990A1 (en) 2016-05-06
HK1247636A1 (zh) 2018-09-28
AU2015338993A1 (en) 2017-05-25
CN115044570A (zh) 2022-09-13

Similar Documents

Publication Publication Date Title
MX2017005672A (es) Erradicacion guiada de arn de virus jc mano y otros poliomavirus.
MX2016002586A (es) Métodos y composiciones para el tratamiento guiado por rna de infección por hiv.
SA519401379B1 (ar) علاج فيروس مرتبط بغدة لمرض هنتنجتون
MX2016011686A (es) Composiciones utiles en el tratamiento de deficiencia de la ornitina transcarbamilasa (otc).
PT3216867T (pt) Método para modificar a sequência de genoma para introduzir mutação específica a sequência de adn alvo por reação de remoção de bases, e complexo molecular nele utilizado
MX2022002624A (es) Edicion del genoma sin nucleasas.
WO2015112896A3 (en) Methods and compositions for sequences guiding cas9 targeting
NZ727481A (en) Methods and compositions for modifying a targeted locus
EA201890012A1 (ru) Способы и композиции для рнк-направляемого лечения инфекции, вызываемой вич
MX2018012880A (es) Metodos para proporcionar arn de hebra sencilla.
MX2016013034A (es) Composicion detergente.
MX2017014908A (es) Proteinas de union triespecificas y metodos de uso.
EA201491539A1 (ru) Улучшение засухоустойчивости у растений: пектинэстераза
PH12016502555A1 (en) Methods of preparing substituted nucleotide analogs
MD4733B1 (ro) Anticorpi anti-TIGIT
EA201791768A1 (ru) Иммуномодулирующие агенты
EA201691581A1 (ru) Способы и композиции для повышения эффективности направленной модификации генов с применением опосредованной олигонуклеотидами репарации генов
SG10201805815YA (en) Rna-guided gene drives
MX2018010483A (es) Inmunogenos para vacunacion contra vih.
MX2021014663A (es) Il-23a y tnf-alfa orientados y compuesto y sus usos.
MX2016008518A (es) Micro-acido ribonucleico (micro-arn) concordante artificial para controlar la expresion genetica y uso del mismo.
IN2015DN04148A (es)
MX2016010100A (es) Secuenciacion libre de error de acido desoxirribonucleico (adn).
WO2015032800A3 (en) Compositions and methods for inducing senescence in cancer cells
PH12017502389A1 (en) Jasmonic acid pathway activator